Guggenheim Capital LLC Boosts Position in Insulet Co. (NASDAQ:PODD)

Guggenheim Capital LLC lifted its position in Insulet Co. (NASDAQ:PODD - Free Report) by 25.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 22,355 shares of the medical instruments supplier's stock after buying an additional 4,555 shares during the period. Guggenheim Capital LLC's holdings in Insulet were worth $5,836,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of PODD. Norges Bank purchased a new stake in shares of Insulet during the fourth quarter worth about $248,806,000. Raymond James Financial Inc. purchased a new stake in Insulet during the 4th quarter worth approximately $69,433,000. Alecta Tjanstepension Omsesidigt acquired a new position in Insulet during the 4th quarter valued at approximately $53,184,000. Artisan Partners Limited Partnership increased its stake in Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after purchasing an additional 149,524 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in shares of Insulet in the fourth quarter worth $28,422,000.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PODD. Royal Bank of Canada initiated coverage on Insulet in a research report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 target price on the stock. StockNews.com lowered Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Stifel Nicolaus lifted their target price on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a report on Friday, February 21st. Raymond James reiterated an "outperform" rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $292.06.

Insider Buying and Selling at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.47% of the company's stock.

Insulet Price Performance

Shares of Insulet stock traded up $7.27 on Wednesday, reaching $251.29. The company's stock had a trading volume of 114,068 shares, compared to its average volume of 713,578. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $17.65 billion, a P/E ratio of 43.40, a PEG ratio of 3.62 and a beta of 1.30. The stock has a 50-day moving average price of $261.71 and a 200-day moving average price of $261.16. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Analysts expect that Insulet Co. will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.